Cargando…

The KRAS-G12D mutation induces metabolic vulnerability in B-cell acute lymphoblastic leukemia

Mutations in RAS pathway genes are highly prevalent in acute lymphoblastic leukemia (ALL). However, the effects of RAS mutations on ALL cell growth have not been experimentally characterized, and effective RAS-targeting therapies are being sought after. Here, we found that Reh ALL cells bearing the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Yan, Fang, Houshun, Chen, Yao, Tang, Yabin, Sun, Huiying, Kong, Ziqing, Yang, Fan, Kirschner-Schwabe, Renate, Zhu, Liang, Toker, Alex, Xiao, Ning, Zhou, Bin-Bing S., Li, Hui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8861657/ https://www.ncbi.nlm.nih.gov/pubmed/35243242 http://dx.doi.org/10.1016/j.isci.2022.103881

Ejemplares similares

P333: SUBCLONAL AND CLONAL VARIANTS IN TP53 AND KRAS COMBINED WITH POOR TREATMENT RESPONSE IDENTIFY A SUBGROUP OF ULTRA-HIGH-RISK PATIENTS OF PEDIATRIC T-LYMPHOBLASTIC LEUKEMIA (T-ALL)
por: Kempter, Tamara, et al.
Publicado: (2023)

KRAS G12C Mutations in NSCLC: From Target to Resistance
por: Addeo, Alfredo, et al.
Publicado: (2021)

Differences in gynecologic tumor development in Amhr2-Cre mice with KRAS(G12D) or KRAS(G12V) mutations
por: Kun, Eucharist H. S., et al.
Publicado: (2020)

Increase of PRPP enhances chemosensitivity of PRPS1 mutant acute lymphoblastic leukemia cells to 5‐Fluorouracil
por: Wang, Dan, et al.
Publicado: (2018)

Targeting KRAS G12C mutations in colorectal cancer
por: Zhao, Ming-He, et al.
Publicado: (2022)

Clinical and genetic characteristics of children with acute lymphoblastic leukemia and Li–Fraumeni syndrome
por: Winter, Greta, et al.
Publicado: (2021)

Computational Analysis of KRAS Mutations: Implications for Different Effects on the KRAS p.G12D and p.G13D Mutations
por: Chen, Chih-Chieh, et al.
Publicado: (2013)

Discovery of Prodrug of MRTX1133 as an Oral Therapy for Cancers with KRAS(G12D) Mutation
por: Ji, Xiang, et al.
Publicado: (2023)

Overcoming Resistance to Drugs Targeting KRAS(G12C) Mutation
por: Jiao, Delong, et al.
Publicado: (2020)

The Research Progress of Direct KRAS G12C Mutation Inhibitors
por: Yang, Ai, et al.
Publicado: (2021)

Adagrasib: A landmark in the KRAS(G12C)‐mutated NSCLC
por: Tian, He, et al.
Publicado: (2022)

KRAS and CREBBP mutations: a relapse-linked malicious liaison in childhood high hyperdiploid acute lymphoblastic leukemia
por: Malinowska-Ozdowy, K, et al.
Publicado: (2015)

Synthetic Vulnerabilities in the KRAS Pathway
por: Roman, Marta, et al.
Publicado: (2022)

KRAS(G12C)-independent feedback activation of wild-type RAS constrains KRAS(G12C) inhibitor efficacy
por: Ryan, Meagan B., et al.
Publicado: (2022)

Chromatin accessibility landscape of pediatric T‐lymphoblastic leukemia and human T‐cell precursors
por: Erarslan‐Uysal, Büşra, et al.
Publicado: (2020)

Mechanisms of Resistance to KRAS(G12C) Inhibitors
por: Dunnett-Kane, Victoria, et al.
Publicado: (2021)

Landscape of KRAS(G12C), Associated Genomic Alterations, and Interrelation With Immuno-Oncology Biomarkers in KRAS-Mutated Cancers
por: Salem, Mohamed E., et al.
Publicado: (2022)

Evaluation of KRAS(G12C) inhibitor responses in novel murine KRAS(G12C) lung cancer cell line models
por: Sisler, Daniel J., et al.
Publicado: (2023)

Corrigendum: The Research Progress of Direct KRAS G12C Mutation Inhibitors
por: Yang, Ai, et al.
Publicado: (2022)

Morphological and Molecular Characterization of KRAS G12C-Mutated Lung Adenocarcinomas
por: Pirlog, Radu, et al.
Publicado: (2022)

Prognostic and therapeutic impact of the KRAS G12C mutation in colorectal cancer
por: Qunaj, Lindor, et al.
Publicado: (2023)

Canadian Consensus Recommendations on the Management of KRAS G12C-Mutated NSCLC
por: Cheema, Parneet K., et al.
Publicado: (2023)

Feedback activation of EGFR/wild-type RAS signaling axis limits KRAS(G12D) inhibitor efficacy in KRAS(G12D)-mutated colorectal cancer
por: Feng, Juanjuan, et al.
Publicado: (2023)

Hypoxic, glycolytic metabolism is a vulnerability of B-acute lymphoblastic leukemia-initiating cells
por: Morris, Vivian, et al.
Publicado: (2022)

TEAD Inhibitors Sensitize KRAS(G12C) Inhibitors via Dual Cell Cycle Arrest in KRAS(G12C)-Mutant NSCLC
por: Tammaccaro, Salvina Laura, et al.
Publicado: (2023)

Subcellular Proteome Analysis Reveals Apoptotic Vulnerability of T-Cell Acute Lymphoblastic Leukemia
por: Song, Xiaolei, et al.
Publicado: (2022)

Clonal evolution mechanisms in NT5C2 mutant relapsed acute lymphoblastic leukemia
por: Tzoneva, Gannie, et al.
Publicado: (2018)

Characterization of a cohort of metastatic lung cancer patients harboring KRAS mutations treated with immunotherapy: differences according to KRAS G12C vs. non-G12C
por: Notario, Lucía, et al.
Publicado: (2023)

Concomitant KRAS mutations attenuate sensitivity of non-small cell lung cancer cells to KRAS G12C inhibition
por: Vaclova, Tereza, et al.
Publicado: (2022)

A saturation mutagenesis screen uncovers resistant and sensitizing secondary KRAS mutations to clinical KRAS(G12C) inhibitors
por: Feng, Siyu, et al.
Publicado: (2022)

Identification of KRAS(G12C) Mutations in Circulating Tumor DNA in Patients With Cancer
por: Thein, Kyaw Z., et al.
Publicado: (2022)

KRAS G12C mutation: from undruggable target to potentially agnostic biomarker
por: El Osta, Badi
Publicado: (2023)

Bcl-xL Is a Key Mediator of Apoptosis Following KRAS(G12C) Inhibition in KRAS(G12C)-mutant Colorectal Cancer
por: Khawaja, Hajrah, et al.
Publicado: (2023)

A Breakthrough Brought about by Targeting KRAS(G12C): Nonconformity Is Punished
por: Ning, Wenjuan, et al.
Publicado: (2022)

Targeting KRAS in Lung Cancer Beyond KRAS G12C Inhibitors: The Immune Regulatory Role of KRAS and Novel Therapeutic Strategies
por: Cucurull, Marc, et al.
Publicado: (2022)

Long non-coding RNAs defining major subtypes of B cell precursor acute lymphoblastic leukemia
por: James, Alva Rani, et al.
Publicado: (2019)

INVOLVEMENT OF KRAS G12A MUTATION IN THE IL-2-INDEPENDENT GROWTH OF A HUMAN T-LGL LEUKEMIA CELL LINE, PLT-2
por: MIZUTANI, NAOKI, et al.
Publicado: (2012)

AZD4625 is a Potent and Selective Inhibitor of KRAS(G12C)
por: Chakraborty, Atanu, et al.
Publicado: (2022)

Comparative proteomics of a model MCF10A-KRas(G12V) cell line reveals a distinct molecular signature of the KRas(G12V) cell surface
por: Ye, Xiaoying, et al.
Publicado: (2016)

Prognostic Implication of KRAS G12C Mutation in a Real-World KRAS-Mutated Stage IV NSCLC Cohort Treated With Immunotherapy in The Netherlands
por: Noordhof, Anneloes L., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_q0i3voak51k9s5jasml6m7j6ls